<DOC>
	<DOCNO>NCT02914314</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( PK ) oral suspension perampanel give adjunctive therapy generate preliminary safety efficacy data pediatric participant , range 1 month less 24 month age , epilepsy .</brief_summary>
	<brief_title>Pharmacokinetic Study With Oral Suspension Perampanel Adjunctive Therapy Pediatric Subjects With Epilepsy</brief_title>
	<detailed_description>This multicenter , open-label study comprise pretreatment , treatment ( core study ) , extension phase design evaluate PK oral suspension perampanel ( target dose 12 milligram per day [ mg /day ] non-enzyme-inducing antiepileptic drug [ non-EIAED ] 16 mg/day EIAED ) give adjunctive therapy participant range 1 month less 24 month ( &lt; 2 year ) age epilepsy . The Pretreatment Phase last 2 week , participant assess eligibility participate study . The Treatment Phase consist 3 period : Titration ( 12 16 week ) , Maintenance ( 4 week ) , Follow-Up ( 4 week ; participant complete Maintenance Period continue Extension Phase participant discontinue study participation ) . The Extension Phase consist 2 period : Maintenance ( 32 36 week ) Follow-Up ( 4 week ) . The maximum total duration treatment participant 52 week , maximum total duration study participant 58 week ( 52 week treatment + 2 week pretreatment + 4 week follow-up ) .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Have minimum weight 4 kilogram ( kg ) ( 8.8 pound [ lb ] ) Have diagnosis epilepsy type seizure accord International League Against Epilepsy 's ( ILAE ) Classification Epileptic Seizures ( 1981 ) . Diagnosis establish least 2 week ( ≤6 month age ) 4 week ( &gt; 6 month age ) Visit 1 , clinical history electroencephalogram ( EEG ) consistent epilepsy ; normal interictal EEGs allow provide participant meet diagnosis criterion ( i.e. , clinical history ) Have brain imaging ( compute tomography [ CT ] magnetic resonance image [ MRI ] ) Visit 1 rule progressive cause epilepsy Have 1 seizure ( ) 4 week Visit 1 Currently treat stable dose ( i.e. , unchanged least 5 halflives ) 1 maximum 3 antiepileptic drug ( AEDs ) ( least 6 , 8 , participant take 1 enzymeinducing AED [ EIAEDs ] maximum 3 AEDs allow . The remain participant take EIAEDs ) . Have current concomitant AED regime stable dose least 2 week ( ≤6 month age ) 4 week ( &gt; 6 month age ) Visit 1 Must discontinue restricted medication least 2 week 5 halflives ( whichever longer ) Visit 1 If enter Extension Phase , must complete last visit Maintenance Period Core Study Have history status epilepticus require hospitalization 3 month Visit 1 Have seizure due treatable medical condition , arise due metabolic disturbance , toxic exposure , active infection Have epilepsy secondary progressive central nervous system ( CNS ) disease progressive neurodegenerative disease , include tumor Have epilepsy surgery Visit 1 Are schedule and/or confirm epilepsy surgery within 6 month Visit 1 Used intermittent rescue benzodiazepine ( i.e. , 1 2 dos 24hour period consider onetime rescue ) 2 time 2 week Visit 1 Prior use felbamate Prior use vigabatrin Are ketogenic diet regimen stable least 4 week Visit 1 Have use drug know influence CNS , dose stabilize least 2 week ( ≤6 month age ) 4 week ( &gt; 6 month age ) Visit 1 Have concomitant illnesses/comorbidities could severely affect participant 's safety study conduct Have evidence clinically significant disease ( e.g. , cardiac , respiratory , gastrointestinal , renal disease ) opinion investigator ( ) could affect participant 's safety study conduct Have clinically significant laboratory abnormality clinically acute chronic disease Have evidence significant active hepatic disease . Stable elevation liver enzymes , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) due concomitant medication ( ) , allow less 3 time upper limit normal ( ULN ) Have clinical evidence significant active hematological disease ; white blood cell ( WBC ) count ≤2500/ microliter ( μL ) ( 2.50 x 10^9/Liter [ L ] ) absolute neutrophil count ≤1000/μL ( 1.00 x 10^9/L ) Have condition may interfere participation study and/or PK study drug Have participate study involve administration investigational drug device within 4 week Visit 1 , within approximately 5 halflives previous investigational compound , whichever longer Have previously participate clinical trial involve perampanel Have clinically significant ECG abnormality , include prolong correct QT interval ( QTc ) define &gt; 450 millisecond ( msec ) Have multiple drug allergy severe drug reaction AED ( ) , include dermatological ( e.g. , StevensJohnson syndrome ) , hematological , organ toxicity reaction</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>epilepsy</keyword>
	<keyword>refractory partial seizure</keyword>
</DOC>